博晖创新：控股股东5.06亿受让河北博晖14.7%股权，并委托托管子公司同步敲定3个浆站审批补充协议

Core Viewpoint - The announcement details a significant equity management agreement between Bohui Innovation and its controlling shareholder, Du Jiangtao, involving a 14.7001% stake in Hebei Bohui Biopharmaceutical Co., Ltd. [1] Group 1: Equity Management Agreement - Du Jiangtao will entrust the management of the 14.7001% stake in Hebei Bohui to Bohui Innovation for free, following a transaction where he acquired the stake from Beijing Tongying Investment Group for 506 million yuan [1] - After the management agreement, Bohui Innovation's total stake in Hebei Bohui will increase to 15.4216% [1] - The agreement allows Bohui Innovation to exercise shareholder rights, excluding profit distribution and residual property rights, which remain with Du Jiangtao [1] Group 2: Supplementary Agreement on Capital Increase - A supplementary agreement was signed between Hebei Bohui and Tongying Group regarding the approval of three single plasma collection stations, with a 24-month deadline for completion [1] - Tongying Group has the option to replace unapproved stations by developing new ones, with a compensation of 80 million yuan per station for any that fail to meet approval [1] - The payment of the second tranche of the equity transfer, amounting to 240 million yuan, is contingent upon the execution of this supplementary agreement [1]